Article

Jyoti D. Patel on Treating Brain Metastases in Lung Cancer Patients

Author(s):

Jyoti D. Patel

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases. Patel is reporting on data presented at the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Related Content
Image of lungs.
July 10th 2025

FDA OKs New Test to Match Lung Cancer Patients With Targeted Therapies

Ryan Scott
The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lung.
June 30th 2025

June Lung Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Datroway received accelerated FDA approval for adults with EGFR+ advanced NSCLC: © stock.adobe.com.
June 23rd 2025

FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer

Spencer Feldman
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.
Image of two doctors with text.
June 20th 2025

Advancements Reshape Treatment for Non-Small Cell Lung Cancer

Ryan Scott
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.